|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2156 USD | +7.75% |
|
+7.85% | -56.71% |
| Market Cap | 11.72M 10.18M 9.48M 8.7M 16.44M 1.12B 16.69M 112M 43.86M 557M 44M 43.03M 1.87B | P/E 2026 * |
21.6x | P/E 2027 * | 3.08x |
|---|---|---|---|---|---|
| Enterprise Value | 11.72M 10.18M 9.48M 8.7M 16.44M 1.12B 16.69M 112M 43.86M 557M 44M 43.03M 1.87B | EV / Sales 2026 * |
0.14x | EV / Sales 2027 * | 0.11x |
| Free-Float |
65.92% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +7.75% | ||
| 1 week | +7.85% | ||
| 1 month | +16.73% | ||
| 3 months | -41.19% | ||
| 6 months | -55.12% | ||
| Current year | -56.71% |
| 1 week | 0.18 |  | 0.22 |
| 1 month | 0.18 | | 0.35 |
| Current year | 0.16 | | 0.59 |
| 1 year | 0.16 | | 1.32 |
| 3 years | 0.16 | | 2.05 |
| 5 years | 0.16 | | 150 |
| 10 years | 0.16 | | 312.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Grigorios Siokas
CEO | Chief Executive Officer | 60 | 26/02/2016 |
Georgios Terzis
DFI | Director of Finance/CFO | 43 | 11/11/2020 |
| Chief Operating Officer | 56 | 01/02/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 13/01/2014 | |
Grigorios Siokas
CHM | Chairman | 60 | 26/02/2016 |
John Hoidas
BRD | Director/Board Member | 59 | 18/11/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 30/07/26 | Buy | Chief Executive Officer | 349,825 | 1.1578% | ||
| 29/07/26 | Free | Chief Financial Officer | 328,407 | 1.0869% | ||
| 29/07/26 | Buy | Chief Executive Officer | 766,284 | 2.5362% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.75% | +7.85% | -76.69% | -86.27% | 11.72M | |
| -1.08% | +1.82% | +23.45% | +112.77% | 100B | |
| +1.30% | +0.88% | +48.20% | +151.48% | 53.87B | |
| -0.68% | +3.52% | +1.73% | +274.52% | 23.74B | |
| +0.60% | +2.93% | -11.45% | -16.16% | 8.37B | |
| -1.29% | +1.85% | -34.29% | -32.97% | 7.56B | |
| -1.53% | +3.21% | -7.85% | -28.92% | 6.92B | |
| -1.14% | -1.47% | +20.50% | +23.29% | 6.16B | |
| -1.83% | -0.87% | -0.52% | +22.61% | 5.29B | |
| -3.96% | +0.23% | +14.86% | +18.33% | 3.7B | |
| Average | -0.19% | +1.85% | -2.21% | +43.87% | 21.59B | |
| Weighted average by Cap. | -0.47% | +1.62% | +22.04% | +119.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 84.3M 73.28M 68.21M 62.62M 118M 8.05B 120M 804M 316M 4.01B 317M 310M 13.43B | 111M 96.32M 89.65M 82.31M 155M 10.58B 158M 1.06B 415M 5.27B 416M 407M 17.66B |
| Net income | - | - |
| Net Debt | - | - |
Employees
163
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | $0.2156 | +7.75% | 5,027,089 |
| 30/07/26 | $0.2001 | +9.52% | 5,396,091 |
| 29/07/26 | $0.1827 | -6.26% | 2,883,202 |
| 28/07/26 | $0.1949 | -6.03% | 2,612,380 |
| 27/07/26 | $0.2074 | +3.75% | 2,904,413 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- COSM Stock
Select your edition
All financial news and data tailored to specific country editions
